A cancer center in New York City safely managed patients with localized prostate cancer during the height of the COVID-19 pandemic in 2020, providing insights for handling a second COVID-19 wave.
Active surveillance may help many men with favorable intermediate-risk prostate cancer to avoid the adverse effects of treatment for 5 years.
Study findings support surveillance for urethral recurrence after radical cystectomy.
Even men who test negative for mutations in the BRCA1/2 DNA repair genes may have increased risk for prostate cancer progression when they have certain family history.
During the COVID-19 pandemic, neoadjuvant ADT has been used as a way to delay initiation of daily radiation therapy, but it may not be appropriate for all men.
In a study of patients on active surveillance, men with greater periprostatic fat had shorter prostate cancer progression-free survival.
Patterns of disease spread varied significantly among patients with clear cell, papillary, and chromophobe renal cell carcinoma and may reflect differences in disease biology, according to investigators.
Investigators found no survival benefit among older patients with esophageal, gastric, pancreatic, or uterine cancer taking aspirin.
Mistrust and concerns about masculinity are important factors that influence Black men’s experience during prostate cancer management.
Higher proportions of patients in the low to middle income brackets were diagnosed with localized renal cell carcinoma in states allowing Medicaid expansion.
